Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-free ruxolitinib ± emapalumab for intermediate/low-risk HLH
ChiCTR2500107364Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ruxolitinib and emapalumab in haemophagocytic lymphohistiocytosis (HLH), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Objective response rate (ORR: CR, PR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ruxolitinibemapalumab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR2500107364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107364.